Related references
Note: Only part of the references are listed.Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
Pravin T. P. Kaumaya et al.
ONCOIMMUNOLOGY (2020)
Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors
Tanios Bekaii-Saab et al.
CLINICAL CANCER RESEARCH (2019)
Cancer immunologists scoop medicine Nobel prize
Heidi Ledford et al.
NATURE (2018)
HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells
Megan Jo Miller et al.
ONCOIMMUNOLOGY (2014)
IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides
Kevin Chu Foy et al.
ONCOIMMUNOLOGY (2014)
Combination Treatment with HER-2 and VEGF Peptide Mimics Induces Potent Anti-tumor and Anti-angiogenic Responses in Vitro and in Vivo
Kevin C. Foy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Share Paper
